Dr. Boon received his
Ph.D. in Biochemistry at the University of Amsterdam. In 2003, he was one of
the founders of Bioceros BV were he currently hold a position of CSO.
production cell lines for the industry and used its proprietary CHO platform to
generate a portfolio of cell lines producing biosimilar monoclonal antibodies.
Since the acquisition of Bioceros by EPIRUS in 2015, he extended this expertise
and developed a complete process toolbox to fit biosimilar CQAs. After the
acquisition of Epirus NL by the Polpharma Biologics group in June 2016, he has
continued to work on biosimilar development and developed the SPOT technology
to improve cell line productivity.
Next to biosimilars, Dr. Boon is also
responsible for the discovery and development of innovative new molecular
antibody entities, which now within the Polpharma Biologics group can be
extended to GMP production and clinical testing. In addition, before he founded Bioceros, he
held positions as CSO for MacroZyme BV, 4AZA Bioscience NV, FF Pharma and VP
Preclinical for PanGenetics BV and Tanox. Dr. Boon is author of over 260 papers
in international scientific journals in the field of medical biotechnology.